SCHEMBL530424

SCHEMBL530424

C=CCC(OC)(OC(=O)O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
TSHR P16473 2/20 0.51
HTT P42858 1/20 0.49
KCNN4 O15554 1/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.43
CES1 P23141 1/20 0.40
CYP2C19 P33261 2/20 0.40
HIF1A Q16665 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15899494 0.81 KCNN4 (0.47) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL28706287 0.80 ALDH1A1 (0.42) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL11775673 0.75 ALDH1A1 (0.57) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL11779225 0.73 ALDH1A1 (0.50) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL10600016 0.73 ALDH1A1 (0.49) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL3999764 0.72 ALDH1A1 (0.67) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL3593284 0.72 KCNN4 (0.53) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL4015143 0.72 KCNN4 (0.53) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL11091632 0.72 CES1 (0.53) ALDH1A1TSHRHTTKCNN4KMT2A
SCHEMBL28022253 0.72 KCNN4 (0.42) ALDH1A1TSHRHTTKCNN4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018213365-A1 COMPOUNDS FOR TREATING DENGUE VIRUS INFECTION AND OTHER VIRAL INFECTIONS DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-11-22 WO disclosed
EP-3347018-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASES Dana-Farber Cancer Institute, Inc. (US) 2018-07-18 EP disclosed
EP-3236959-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Dana Farber Cancer Institute, Inc. (US) 2017-11-01 EP disclosed
WO-2017044858-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-03-16 WO disclosed
WO-2016105528-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-30 WO disclosed
EP-2956138-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF Kala Pharmaceuticals, Inc. (US) 2015-12-23 EP disclosed
WO-2015057958-A2 ENTEROBACTIN CONJUGATES AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2015-04-23 WO disclosed
EP-2831079-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF Agency For Science, Technology And Research (SG) 2015-02-04 EP disclosed
WO-2014127214-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF KALA PHARMACEUTICALS, INC. (US) 2014-08-21 WO disclosed
WO-2013147711-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-10-03 WO disclosed
EP-2598522-A2 RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF Smartcells, Inc. (US) 2013-06-05 EP disclosed
EP-2582836-A2 PRPK-TPRKB MODULATORS AND USES THEREOF Makoto Life Sciences, Inc. (US) 2013-04-24 EP disclosed
WO-2012015691-A2 RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. (US) 2012-02-02 WO disclosed
WO-2011160042-A2 PRPK-TPRKB MODULATORS AND USES THEREOF MAKOTO LIFE SCIENCES, INC. (US) 2011-12-22 WO disclosed